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Obesity and type 2 diabetes are recognised risk factors for the development of some cancers and, increasingly, predict more
aggressive disease, treatment failure, and cancer-specific mortality. Many factors may contribute to this clinical observation.
Hyperinsulinaemia, dyslipidaemia, hypoxia, ER stress, and inflammation associated with expanded adipose tissue are thought
to be among the main culprits driving malignant growth and cancer advancement. This observation has led to the proposal
of the potential utility of “old players” for the treatment of type 2 diabetes and metabolic syndrome as new cancer adjuvant
therapeutics. Androgen-regulated pathways drive proliferation, differentiation, and survival of benign and malignant prostate
tissue. Androgen deprivation therapy (ADT) exploits this dependence to systemically treat advanced prostate cancer resulting
in anticancer response and improvement of cancer symptoms. However, the initial therapeutic response from ADT eventually
progresses to castrate resistant prostate cancer (CRPC) which is currently incurable. ADT rapidly induces hyperinsulinaemia
which is associated with more rapid treatment failure. We discuss current observations of cancer in the context of obesity, diabetes,
and insulin-lowering medication. We provide an update on current treatments for advanced prostate cancer and discuss whether
metabolic dysfunction, developed during ADT, provides a unique therapeutic window for rapid translation of insulin-sensitising
medication as combination therapy with antiandrogen targeting agents for the management of advanced prostate cancer.
1. Obesity, Type 2 Diabetes and
Prostate Cancer
1.1. Obesity and Cancer Risk. Worldwide rates of obesity have
doubled in a generationwith a global estimate of∼500million
obese adults (with an additional 1.5 billion overweight) being
followed by a generation of 40 million overweight children
[1]. In both industrialised and developing countries these
staggering numbers pose a soaring economic and health
care burden as a result of chronic comorbidities includ-
ing increased rates of cardiovascular disease, hypertension,
stroke, and type 2 diabetes (T2DM) [2].
Obesity is also a risk factor for a growing number
of cancers. Retrospective observational studies and meta-
analyses, using body mass index (BMI; mass (kg)/height
(m2)) as a measure of adiposity, have demonstrated an
increased risk of breast, ovarian, colorectal, bladder, kid-
ney, and endometrial cancers with increasing BMI [3–6].
Similarly, obesity attributes a 12% increased risk of prostate
cancer diagnosis [3] although studies have varied, with some
showing a weak association (relative risk (RR): 1.05 [7]),
or a significant risk of high-grade and metastatic cancers,
(RR: 1.22–1.55) but not low-grade prostate cancer [8]. These
differences may be accounted for by differences in detection
bias (using cohorts of closelymonitored patients, for example,
during diabetes screening), differences in time of “disease-
free” follow-up and patient age [9]. Also, these studies may
be limited by the use of BMI as a measurement of adiposity,
underscored by the recent finding that specific measurement
of visceral fat volume, the more metabolically compromised
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fat depot in obesity, may provide a much stronger statistical
correlate with disease-free survival in cancer patients than
BMI [10]. Adding to these statistical differences, there are
more practical difficulties of prostate cancer detection in
obese subjects. Measurements of prostate specific antigen
(PSA), a serum biomarker used for screening, which can also
be elevated in nonmalignant disease such as benign prostatic
hyperplasia (BPH) or with aging, can be difficult to interpret
in obese patients; both lower levels of PSA, due to increased
blood volume and increased PSA levels concomitant with
increased incidence of BPH [11], have been reported in obese
men [12]. Notwithstanding, a recent study by Fowke et al. [9]
has found that the association between obesity and prostate
cancer persists when these factors are taken into account.
1.2. Obesity and Cancer Progression. What is indisputable
from the epidemiology is the impact of obesity on cancer
behaviour. Obesity is consistently identified as a significant
risk factor for more aggressive disease and an independent
predictor of recurrence and cancer-specific mortality for
breast [13], endometrial, ovarian [14], and bladder cancer
[5] as well as prostate cancer [9, 15]. Men with higher BMI
are more likely to be diagnosed with higher-grade cancers
and higher Gleason scores and suffer an increased incidence
of recurrence [3, 7, 15, 16] and increased cancer-specific
mortality than men with a healthy BMI [16–18].
The molecular link(s) between obesity and malignancy is
the subject of current research and has been recently reviewed
[19–21]. Obese adipose tissue creates a hypoxic environment,
as well as an overproduction of ROS resulting in oxidative
and ER stress [22]. In addition, many bioactive molecules are
altered in obesity which could contribute to neoplasia and
cancer progression [21] including lipid mediators, inflam-
matory cytokines, and hormones/growth factors. As adipose
tissue expands, a proinflammatory environment develops
with increased secretion of cytokines such as IL-6, TNF𝛼,
and MCP1, from both adipocytes and resident immune
cells. These, in turn, act as chemoattractants for further
immune cells and thus create a feed-forward loop, perpet-
uating immune cell infiltration and cytokine production.
Cell signalling is impacted, particularly insulin signalling in
local and peripheral tissue (e.g., muscle and liver) leading
to systemic insulin resistance [23] and sustained elevated
circulating insulin levels.
Dysregulated lipid flux in obesity results in decreased
HDL cholesterol and elevated LDL, circulating levels of
triglycerides and free fatty acids which have been shown
to promote prostate cancer cell survival [24, 25]. Inflam-
matory lipid mediators such as arachidonate and down-
stream signalling lipids, such as eicosanoids, prostanoids, and
leukotrienes, are also increased [21, 26] and could potentially
impact tumour cell biology; arachidonate can also promote
steroid hormone production in prostate cancer cells [27].
Altered hormonal profiles are also a hallmark of meta-
bolic dysfunction with modulated adipokine production
and secretion, including increased leptin, proportional to
adipose mass, while adiponectin shows an inverse relation-
ship [28]. Elevated leptin levels have been associated with
breast, prostate and colon cancer progression, and leptin
promotes in vitro cell proliferation and invasion [9, 29], as
well as independently modulating inflammation. Reduced
adiponectin, which purportedly puts a brake on malignant
cell proliferation, has also been observed in a range of cancers
[30] including prostate cancer.
However, it is hyperinsulinaemia, as a result of insulin
resistance in classical metabolic tissues, which has been
identified as a highly significant risk factor to progression of
prostate and other cancers [14]. In prostate cancer, elevated
insulin or C-peptide levels (used as a normalised surrogate)
have recently been shown to significantly correlate with high-
grade prostate cancer and worse patient prognosis [16, 31–
36], more significantly than BMI alone, suggesting that at
least part of the effect of increased BMI on prostate cancer
mortality is related to coincident hyperinsulinaemia [33].
Similarly, a strong association with high C peptide and the
development of high-grade prostate cancer of Gleason grade
7 or greater has been identified, independent of BMI [36].
Baseline insulin levels at time of prostate cancer diagnosis
have also been shown to be the most significant predictor
of lethal prostate cancer, strongly suggesting that insulin
is a major factor in prostate cancer progression associated
withmetabolic dysfunction [35]. Chronically elevated insulin
facilitates in tumour tissues increased activation ofmitogenic,
anabolic, and prosurvival pathways with the increased levels
of insulin and concomitant elevated insulin-like growth
factor 1 (IGF-1) [37, 38]. We have also recently reported
that insulin regulates the expression of novel gene tran-
scripts/splice variants in tumour tissue [39]. In addition,
many tumour types, including prostate tumours, upregulate
the expression of related insulin receptor (INSR), IGF-1
receptor (IGF-1R), and hybrid INSR/IGF-1Rs [31, 40] further
promoting insulin-driven cancer survival pathways [41]. And
notably, an increased ratio of INSR/IGF1R expression has
recently been described in prostate tumours and adjacent
tissue [42], which suggests specifically that insulin signalling
plays a key role in these tumours.
Together, the altered hormonal and inflammatory milieu
of obesity may contribute significantly to cancer growth and
progression via promoting mitogenesis (e.g., leptin, IGF-1,
insulin), angiogenesis (e.g., VEGF, IL6, IL8), and invasion
(e.g., leptin, IL6, PAI-1, CCL5, CCL2) [19].
1.3. Diabetes and Cancer Risk. Obesity is a major risk factor
for the development of T2DM, a condition defined by hyper-
glycaemia in a background of insulin resistance in metabolic
organs (e.g., muscle and liver). Diabetes generally develops
as pancreatic 𝛽-cells are unable to respond adequately to
increased insulin required to maintain normoglycaemia.
Diabetes has been independently associated with increased
risk of several cancers including colon, pancreatic, and breast
cancer [43, 44]. In contrast, some studies suggest that diabetes
may be protective of prostate cancer risk [45–47], perhaps due
to the typically decreased levels of androgens in these men;
prostate tumours are fuelled by androgens for growth and
survival, and testosterone levels are typically lower in men
with diabetes [46–48]. However, this is also confounded by a
lack of separation of men taking diabetic control agents, such
as metformin [46, 49]. Although diabetes is associated with
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a lower incidence of prostate cancer, postdiagnosis, diabetes
increases the risk of cancer-specificmortality [50], suggesting
that similar risk factors contributing to cancer progression
are involved in prostate cancer as other tumour types. Large
cohort studies of diabetic patients are partly compromised
by the fact that many studies reporting the relative risk
of cancer with diabetic status have not separately defined
the proportion of type 1 and type 2 diabetes within these
studies, nor analysed the cohorts individually or based on
medications [46, 49, 51]. While highlighting the association
betweenhyperglycaemia per se andprostate cancer,metabolic
risk factors associated with T2DM with potential links to
cancer, such as hyperinsulinaemia and inflammation, are
likely to lose statistical impact by combining diabetic sub-
types; the rate of obesity in T2DM is 52% (86% overweight),
compared to 16% in type I diabetes (55.3% overweight), and,
as such, the metabolic contribution to malignancy, described
above, would be expected to have significantly different
impact [52]. Furthermore, type 1 diabetes is characterised
by a loss of insulin and use of exogenous insulin analogues
whereas T2DM is treated with a range of medications
includingmetformin, sulphonylureas, and insulinwhich vary
in cancer risk profiles [53–55], some conferring protection,
(metformin) and others increasing risk (sulphonylureas and
insulin analogues) [45, 53]. Indeed, this observation has
led many to speculate on the potential utility of diabetes
treatments as adjuvant cancer therapeutics.
2. Emergence of Insulin-Sensitising
Drugs in Cancer
The observation of increased cancer risk with obesity and
diabetes has led to the somewhatmore hopeful speculation of
potential therapeutic benefit of insulin-sensitizing drugs with
themajor clinical outcomeof lowering systemic insulin levels.
Studies have shown some cancer survival benefit in type 2
diabetes patients treated with the biguanide and metformin
compared to those treated with insulin or sulphonylureas
(stimulate insulin secretion from pancreatic 𝛽-cells) [53,
56–58]. In addition, the thiazolidinedione class of PPAR
agonists [59], the lipase inhibitor, orlistat, and cholesterol-
lowering statin class of drugs [60, 61] have also been shown
to associate with lower cancer risk. A growing body of in vitro
evidence is beginning to provide mechanistic detail to these
observations.
2.1.Metformin. Metformin,whichworks in part by activating
AMP-activated protein kinase (AMPK), is used clinically
in obese and diabetic patients to normalise circulating
insulin levels primarily via reduced hepatic glucose output
and improve insulin/receptor interactions. Recent clinical
studies have suggested that metformin may improve patient
outcomes in prostate and other cancers [33, 53, 62–64].
Amongst diabetic populations, metformin has the lowest
cancer mortality profile when compared to sulphonylurea or
insulin treatment [53, 56–58, 63], in a dose and duration of
treatment-dependent manner.
Apart fromnormalising systemic insulin, the intracellular
effects of metformin in tumour cells have been the subject
of recent study and review [41]. Metformin can potentiate
several pathways to prevent tumour cell growth and invasion,
primarily via blocking anabolic pathways such as lipognesis
and protein translation, preventing mitosis and increasing
sensitivity to chemotherapy.
The activation of AMPK in cancer cells blocks cell
proliferation by negatively regulating mammalian target of
rapamycin (mTOR) control of protein synthesis [43, 65–67].
Selective suppression of translation of mRNAs-encoding cell
cycle regulators within the mTOR/EIF4E pathway by met-
formin has been recently described [68], and the expression
of many genes involved in mitosis, such as tubulins, histones,
and kinesins is decreased by metformin [69]. AMPK acts as
an intracellular energy sensor, responding to fluctuations in
the ratio of AMP and ATP. In times of energy deficit (high
AMP:ATP ratio), the activation of AMPK blocks anabolic
pathways and promotes the generation of ATP (e.g., oxidative
phosphorylation, 𝛽-oxidation). Thus, metformin effectively
blocks lipogenesis by inhibiting activation or expression of
lipid biosynthesis enzymes such as acetyl Co-A carboxylase
(ACC) and fatty acid synthase (FASN), key regulators of
the metabolic reprogramming identified in prostate cancer
[70]. Likewise, the enzyme responsible for steroid (estrogen)
production, aromatase, is decreased in breast adipose tissue
with metformin use [71].
Another proposed mechanism of metformin is pre-
venting pathways which lead to invasion and metastasis
evidenced by the demonstration of metformin to prevent
invasiveness in cancer models [72, 73]. Similarly, it has been
reported in pancreatic cancer cells that metformin reversed
cell invasion by facilitating the reexpression of critical RNA
species required for phenotypic maintenance [74]. Based
on these results, targeting AMP-activated protein kinase
(AMPK) has been proposed as a therapeutic strategy in
cancer [75, 76].
2.2. Lipid Modulators: Orlistat and Statins. The pancreatic
lipase inhibitor, orlistat, has its primary effect on reducing
hydrolysis of triglycerides and preventing the absorption of
dietary free fatty acids. Its major clinical benefit in obesity
is preventing caloric intake, thus, reducing circulating lipid
levels and improving insulin sensitivity [77]. FASN expres-
sion is upregulated in a number of cancers including ovarian,
breast, and prostate [78–80] so the discovery that orlistat was
a novel inhibitor of FASN [81] triggered numerous studies
into the efficacy of orlistat as a therapeutic agent for cancer.
orlistat has been shown to prevent in vitro and in vivo growth
of the prostate cancer cell line PC3 and to induce apoptosis.
[81].The inhibition of FASNwith orlistat also causes cell cycle
arrest and induces caspase-mediated apoptosis [82] and has
also been shown to increase sensitivity to chemotherapeutic
compounds [83, 84].
Statins lower cholesterol levels by inhibiting a criti-
cal enzyme for cholesterol synthesis, HMGCoA reductase
(HMGCR), which is upregulated in CaP and breast cancer
tissue [85]. The role of HMGCR in cholesterol synthesis, and
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a precursor to steroid hormone synthesis, is likely to be an
important link in the association between statin use and a
lower rate of prostate cancer recurrence [26, 86, 87]. Indeed,
it has been shown that statin use inversely correlated with
the risk and progression of prostate cancer [88, 89]. In a
large-scale study by Loeb et al. men on statins were older
and had high BMI at time of radical prostatectomy, but,
despite these increased risk factors, the patients on statins
had lower PSA, as well as lower Gleason score, lower tumour
volumes, smaller surgical margins, and less risk of biological
recurrence [88]. Other studies demonstrate a significant
decrease in advanced and metastatic disease [88, 90].
2.3. Thiazolidinediones. Thiazolidinediones (TZDs) are a
class of insulin-lowering (insulin-sensitising) drugs which
activate the PPAR family of nuclear receptors, with predom-
inant affinity for PPAR𝛾, highly expressed in prostate cells
[91]. Several TZDs are used clinically to treat type 2 dia-
betes, including pioglitazone, troglitazone, rosiglitazone, and
ciglitazone. Their use in other diseases with hallmark hyper-
insulinaemia (e.g., polycystic ovarian syndrome and some
lipodystrophies) is the subject of an ongoing research [92]. A
largemeta-analysis comparingTZDuse and cancer incidence
[93] found a decreased risk of colorectal, lung, and breast
cancers with TZDs, but specifically, the use of pioglitazone—
which extended protection to prostate and renal cancer
as well. This finding has also been demonstrated in other
studies where TZD use is associated with improved survival
of diabetic prostate cancer patients [59]. In prostate cancer
cell models, troglitazone reduced in vitro and in vivo cell
growth via ERK-dependent regulation of p21 and cMyc [94]
and inducing apoptosis [80]. Prostate-specific knockdown of
PPAR𝛾 resulted in the dysregulation of cell cycle control and
lipid signalling networks [95]. In ovarian models, differential
efficacy of ciglitazone and troglitazone (but not rosi- or
pioglitazone) was observed with respect to cell cycle arrest,
increased caspase activation, and evidence is now mounting
that thismay occur via PPAR𝛾-independentmechanisms [96,
97]. In prostate cancer cells TZDs induced cell senescence, via
PPAR𝛾-dependent (rosiglitazone) and -independent (ciglita-
zone) mechanisms [98]. Studies in lung cancer cell models
have reported TZD treatment works directly on cancer cells
to decrease pathways that lead to invasion such as epithelial-
to-mesenchymal transition (EMT) via Smad-dependent and
-independent mechanisms [99]. Taken together, there is
compelling evidence that current antidiabetes treatments
offer therapeutic benefit in cancer.
2.4. Exogenous Insulin Analogues. The efficacy of insulin-
lowering therapies in reducing risk and progression of cancer
is highlighted by the converse, that is, increased risk of cancer
in diabetic patients treated with insulin analogues. These
include fast-acting analogues such as Aspart and Lispro with
similar INSR but reduced IGF1R-binding affinities compared
to native insulin [100], and Glargine and X10 with increased
IGF1R affinity compared to insulin, and sustained binding
kinetics [101, 102]. Nevertheless, the clear benefit of good
glucose control in diabetes is worth bearing inmind in regard
to cancer risk.
3. Prostate Cancer as a Candidate for
Insulin-Lowering Therapy
3.1. Advanced Prostate Cancer. At current rates, prostate
cancer will affect oneman in seven and is the leading cause of
cancer deaths in men in western countries [103]. For rapidly
advancing, localised disease, patients are generally treated
with radical prostatectomy or radiation therapy with a high
rate of success (>90%) [104]. However, up to 25% of patients
will recur, heralded by a biochemical recurrence measured
as a rising PSA, and require secondary treatment. Prostate
tumours depend on androgen signalling for growth and sur-
vival, and this dependence has rationalised the standard treat-
ment for metastatic prostate cancer, androgen-deprivation
therapy (ADT), for decades [105, 106]. The most common
method of ADT uses luteinising hormone-releasing hor-
mone (LHRH) agonists or antagonists to medically disrupt
hypogonadal feedback loop to inhibit testicular testosterone
production, or to a lesser degree direct orchiectomy.An initial
surge of testosterone in response to LHRH agonists is often
blunted with coadministration of androgen receptor (AR)
antagonists (e.g., bicalutamide and flutamide). ADT results
in anticancer response and prolongs cancer control; however,
after a median time of 12 to 33 months, the cancer resurges,
with a second PSA rise, despite castrate levels of serum
testosterone (<20 ng/dL) [107]. This disease stage is referred
to castrate-resistant prostate cancer (CRPC) and traditionally
has had limited effective treatment options, finding that
effective therapy for CRPC has been the focus of intense and
productive research in recent years with a surge of new agents
approved and, in development, many of which re-targeting in
new ways the androgen axis.
4. Current Therapy for CRPC
While chemotherapies such as docetaxel [108, 109] and
cabazitaxel [110] provide some survival benefit in metastatic
CRPC, therapeutic strategies are increasingly focussing on
the inhibition of androgen signalling as evidence mounts
that CRPC continues to utilize androgens for tumour growth
and driving cell survival pathways [111–113]. There are sev-
eral mechanisms by which prostate tumours may reactivate
androgen signalling, including gain-of-function mutations
or alternative splicing of the androgen receptor (AR) that
broaden its range of ligands to other steroid hormones
(e.g., progesterone, estrogen, and cortisol), antiandrogens
(e.g., flutamide and bicalutamide) [114–116], or confer ligand-
independent activity [117]. The development of a hypersen-
sitive receptor, via overexpression of AR and/or receptor
stabilization, provides a secondmechanism that results in AR
activation even at low levels of androgens [118–121]. A further
mechanism by which CRPC maintains AR signalling is by
producing its own androgens from both adrenal conversion
and intratumoural intracrine steroidogenic pathways. The
observation that, despite low serum levels, intraprostatic
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levels of DHT and testosterone were high in men treated
with ADT [122], up to 50% of intraprostatic levels measured
in eugonadal men [122–125], led to the finding by us and
others that, under androgen deprived conditions, enzymes
required for conversion of adrenal androgens and de novo
intratumoural androgen synthesis are upregulated in prostate
cancer cells [113, 126, 127].Thus, no longer reliant on testicular
androgens, AR signalling can resume within the tumour
microenvironment, leading to the development of CRPC.
These factors combined have rationalised the recent surge in
new antiandrogens for the treatment of CRPC, which target
the AR and inhibit activity, or block rate-limiting enzymes in
de novo steroid synthesis.
4.1. New Inhibitors Targeting the AR. A tranche of new-
generation antiandrogens have recently emerged from pre-
liminary clinical trials with promising results; MDV3100
(Medivation Inc.), a small molecule AR antagonist, has
recently been FDA approved for secondary hormone treat-
ment for CRPC under the trade name of Enzalutamide.
MDV3100 binding the AR blocks ligand binding, impairs
nuclear translocation of the receptor, and induces a confor-
mational change that prevents AR transcription and cofactor
recruitment [128]. MDV3100 has from 5- to 10-fold greater
binding affinity for the AR than bicalutamide or Casodex,
but, unlike bicalutamide, has no partial agonist activity
[128] and, excitingly, may also block constitutively active
AR splice variants [129]. A second AR-antagonist, ARN509
(Aragon Pharmaceuticals), similarly binds AR, prevents
nuclear translocation and transcription, and, in early clinical
trials, has shown promise for efficacy at lower doses than
MDV3100 [130].
4.2. New Inhibitors Targeting Steroid Synthesis. Antiandrogen
therapies are also aimed at inhibiting androgen biosynthesis.
Androgens are synthesized from cholesterol via steroidogen-
esis. Multifunctional enzyme CYP17A1 catalyzes two impor-
tant steps in the steroidogenesis pathway: the conversion of
progestogens to androgen precursors and subsequent con-
version to androgens (DHEA and androstenedione). DHEA
and androstenedione are then converted to testosterone
via 17-𝛽-hydroxysteroid dehydrogenase (17BHSD) and then
to DHT via RDH5. Currently, both ketoconazole (a pan-
CYP inhibitor, Figure 1) and aminoglutethimide (inhibitor of
CYP11A1) are used to block key enzymes in the androgen
synthesis pathway in combination with ADT.
Improved, specific CYP17A1 inhibitors such as abi-
raterone (Janssen) FDA, TAK-700 (Takeda/Millenium Phar-
maceuticals), and TOK-001 (Tokai Pharmaceuticals) are now
in various stages of clinical assessment for adjuvant use
with LHRH agonists. abiraterone, unlike previous CYP17
inhibitors, has a 3-pyridyl substitute and 16,17 double bond,
which makes it a highly specific, potent, and irreversible
inhibitor of both the hydroxylase and lyase activity of
CYP17A1 [131–133]. abiraterone acetate, the oral drug precur-
sor of abiraterone, has been FDA approved with trade named
Zytiga for CRPC treatment, in settings of postdocetaxel [134]
and now prechemotherapy [135]. TAK-700 is a nonsteroidal
imidazole, a potent inhibitor of CYP17A1 lyase activity, with
weak inhibition of hydroxylase activity and thereforemay not
require concomitant control of rise in mineralocorticoids as
is needed for abiraterone. TAK-700 is currently undergoing
Phase I/II clinical trials. A thirdmolecule, 17-benzoimidazole
TOK-001, has combinedCYP17/AR inhibitor activity and has
shown promising results in preclinical studies including a
remarkable decrease in AR protein expression and regression
of in vivo xenograft tumours [136].
While much progress has been made in the emergence
of new drugs suppressing AR activity in prostate cancer,
the unfortunate reality is that, even in these early trials,
patients have become resistant to these new therapies [137].
Both abiraterone and MDV3100, currently the only new-
generation drugs with FDA approval, show survival benefits
of 4.6 months [134] and 4.8 months [138], respectively, in
the postdocetaxel setting. In the prechemotherapy setting,
abiraterone treatment offers an increased time to biochemical
recurrence of 11.1 months [134, 135]. Early trial results show
that MDV3100 has improved efficacy, with an extra 5.3
months to biochemical failure compared to postdocetaxel
[138]. The persistent capability of CRPC to become resistant
to variousmeans of suppression ofAR signalling suggests that
a multipronged approach to cancer treatment is required and
leads to the research question: what drives prostate cancer
aggressiveness and CRPC progression?
5. Metabolic Dysfunction Caused by ADT
Accelerates CRPC
Metabolic dysfunction is a well-established side effect of ADT
[34, 139].The response to suppression of testosterone in men,
irrespective of patient BMI at treatment commencement,
includes gain of fat and loss of muscle mass, increased LDL
and triglycerides, hypertension, and increased fasting glucose
[140]—metabolic symptoms which significantly overlap the
comorbidities of obesity. Abrupt withdrawal of androgens
by ADT results in hyperinsulinaemia and loss of insulin
sensitivity reflected by increased homeostatic model assess-
ment (HOMA) score, within 2 weeks [141], suggesting a
direct effect of ADT and is independent of fat mass and
age [139, 142]. Major findings from recent studies [36, 143]
and our own recent pilot study of men receiving ADT
demonstrated a strong trend between elevated C-peptide and
more rapid progression to CRPC. This phenomenon appears
to be due to a direct inverse relationship that exists between
the testosterone and insulin hormonal axes in men [144–
149]; testosterone is inversely linked to insulin sensitivity
and insulin-sensitisingmedication increases testosterone [59,
150]; however, the exact mechanisms of crosstalk between
these pathways are not well understood [151, 152].
Traditionally, insulin has been considered a hormone-
controlling metabolic regulation; however, the pathways
activated by insulin, including phosphatidylinositol 3-kinase
(PI3K)/Akt and Ras/MAPK pathways, have many well-
characterised downstream effects relevant to CRPC progres-
sion, including the inhibition of apoptosis (e.g., via FOXO
and BAD-mediated pathways) [118, 153] and stimulation of
cell proliferation (e.g., via mTOR) (Figure 1, insulin-signalling
pathways) [40, 154]. Hyperinsulinaemia, secondary to ADT
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prostate cancer progression followingADT.Androgen signalling is targeted using directAR inhibitors. Bicalutamide (Casodex) andMDV3100
directly bind AR to prevent activity. Ketoconazole, abiraterone (Zitega), and TOK-001 have dual inhibition of CYP17A1 lyase/hydroxylase
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prostate cancer cells. Insulin can accelerate de novo androgen synthesis [153], which provides the AR with several suitable ligands (Key)
and allows AR-mediated transcription of genes needed for CRPC progression. Additionally, insulin signalling may activate several AR-
independent pathways (e.g., antiapoptosis and cell proliferation). Insulin-sensitizing drugs, such as metformin, orlistat, thiazolidinediones,
and statins effectively block insulin-induced effects such as proliferation, lipid, and cholesterol synthesis and, hence, may be effective for the
treatment of prostate cancer.The role of AR onAMPK-mediated cell response is still unclear andmay be dependent on availability of cofactors
(LKB1 versus CAMKK2).
treatment, would be expected to increase the activation of
these pathways in the relatively insulin-sensitive prostate
tumour. Furthermore, increased insulin signalling would
be facilitated by increased INSR expression in advanced
prostate cancer [31] (Lubik, Gunter, Nelson, unpublished
data). We have recently demonstrated that insulin acceler-
ates intratumoural androgen synthesis [155], a major path-
way contributing to progression to CRPC. But, insulin is
expected to upregulate a number of pathways leading to
ADT failure [156, 157]. Regulation of molecules by signalling
downstream of insulin/IGF-1R has also been implicated in
CRPC progression, including COX2 [158–160], and nuclear
AR chaperone, Hsp27 [161, 162]. Notably, obesity and dia-
betes may independently regulate these molecules [163–
165]. Moreover, serum from obese mice has been shown
to induce an invasive phenotype in prostate cancer cell
lines [166] suggesting that metabolic changes associated with
obesity (including elevated insulin) may drive metastatic
transformation. However, chronic insulin signalling in the
context of ADT might be complex and highly differenti-
ated from those observed in other cancers [167]. Potential
crosstalk between AR and insulin-signalling cascades [168–
171] emphasises the potential insulin-driven CRPC pro-
gression. And recent studies have implicated the PI3K/Akt
pathway activation to inhibit AR signalling [172] resulting in
androgen-independent growth. Several other growth factors
and cytokines upregulated in obesity, such as IL-6, IL-8,
IGF-1, and TGF𝛽, may also influence prostate cancer cell
proliferation [173–175].
6. A Future for Combined Therapy
Epidemiological evidence, coupled with the upregulation of
insulin-signalling components and insulin-mediated upreg-
ulation of CRPC pathways in prostate cancer cells, has col-
lectively rationalised a multidisciplinary approach to treating
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advanced prostate cancer that incorporates antiandrogen
therapy with simultaneous treatment ofmetabolic side effects
induced by ADT.
Metformin has been the first drug to be explored in this
area, with ongoing clinical trials using metformin during
active surveillance (NCT01733836) and in combination with
ADT (NCT01620593) testing the efficacy of metformin in
stabilising/normalising circulating insulin levels. Metformin
has a well-characterised safety profile and, while it effectively
decreases hyperglycaemia, does not affect blood glucose
levels in nondiabetic patients. Metformin may also act
directly on tumour cells to reduce cancer cell proliferation
via the inhibition of anabolic pathways such as lipogenesis
starving the major bioenergetic pathway in prostate cancer
cells. However, the ability of the major intracellular target
of metformin, AMPK, to potentiate insulin action on cell
growth and survival may have more complex regulation in
prostate cancer cells via interaction with AR-regulated genes;
activated AMPK may potentiate increased prostate cancer
cell proliferation and migration when activated downstream
of the androgen receptor (AR) [176, 177] under the control
of a master regulator calcium/calmodulin-dependent protein
kinase kinase 2 (CAMKK2) [177]. AR directly regulates
CAMKK2 and is highly expressed in normal prostate with
elevated expression in both AR-sensitive and CRPC models
of prostate cancer [176, 177]. In studies where metformin
activation of AMPK results in cessation of cancer cell growth,
signalling is through LKB-1 tumour suppressor [178] sug-
gesting that AMPK is a potentially bifunctional modulator,
particularly relevant in the prostate cell, dominated by AR-
regulated transcriptional landscape, and conversely may be
dysregulated with AR as occurs in prostate cancer.The ability
of insulin to accelerate de novo steroid synthesis in prostate
cancer cells suggests that drugs targeting steroidogenesis
in combination with insulin-lowering therapies would be
beneficial; trials combining abiraterone and metformin are
yet to commence (NCT01677897).
Atorvastatin (statin) is also currently under examina-
tion for treatment in prostate cancer in combination with
ADT (NCT01555632). Statins target cholesterol synthesis,
the substrate for steroidogenesis and in adrenocortical cells
and the ovaries, have been shown to decrease steroidogenic
enzymes CYP11A1, HSD3B, and CYP17A1 [179]. Statins were
able to slow or halt progression to castrate resistance in
LNCaP xenograft models [180] and inhibited prostate cancer
growth with greater potency in androgen-deprived condi-
tion. The clinical benefit of metformin combined with statin
for treatment of biochemical recurrence following primary
treatment failure (PSA increase following prostatectomy
or radiation therapy) is also under clinical investigation
(NCT01561482), targeting lipid/cholesterol metabolism and
hyperinsulinaemia in an effort to slow progression.
The dual activity of orlistat, reducing dietary lipid absorp-
tion and as an inhibitor of FASN, could also have an adjunct
role to play in mitigating the side effects of ADT which
may promote cancer progression. orlistat could potentially be
used to reduce systemic dyslipidaemia, normalising free fatty
acid and cholesterol levels and thereby reducing substrate
for tumour metabolism and biosynthesis. However, dietary
fats make up only a fraction of the lipid available to prostate
cancer cells, which almost universally upregulate FASN [181].
7. Conclusion
Prostate cancer is the most common cancer in men [103]
and, given its long natural history and with onset beginning
in 5-6 decades of life, will continue to rise and plague our
ageing population. At the same time we face the growing
epidemic of obesity while the risk of aggressive prostate
cancer is increased 3-fold with obesity. First-line therapies
for localised cancer will fail in nearly 25% of prostate cancer
patients, and these men will subsequently be treated with
ADT [182]. While effectively treating prostate cancer, ADT
induces hyperinsulinaemia [182–185] which independently
acts on prostate cancer to upregulate lipid and steroid
synthesis and contribute to CRPC progression and which
may promote metastases, tumour growth, and treatment
resistance. Standard chemotherapeutic agents have had lim-
ited benefit in CRPC, and there has been quite promising
development of next-generation therapies targeting androgen
synthesis and directly AR in combination with ADT. These
new targeted agents are generally well-tolerated and signif-
icantly improve survival; however, most patients ultimately
fail, highlighting the urgent need to understand mechanisms
underlying treatment resistance and find rationally informed
combined and/or sequential treatment options. An existing
toolbox of well-tolerated insulin-lowering therapies has accu-
mulated over several decades to treat type 2 diabetes and
metabolic complications associated with obesity. Currently,
ADT-induced hyperinsulinaemia is not addressed in prostate
cancer patients, despite a significantly increased risk of
cardiovascular and cancer-related mortality in these patients
[186]; the combination of ongoing research and clinical trials
will determine the benefit of adjunct antiinsulin therapy to
current standard and emerging prostate cancer treatments.
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